Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Veracyte launches new genomic test to improve lung cancer diagnosis

Veracyte, Inc., a molecular diagnostic company pioneering the field of molecular cytology, today announced the launch of its Percepta Bronchial Genomic Classifier, a new genomic test to resolve ambiguity in lung cancer diagnosis. The company will soon begin testing patient samples in its CLIA-certified laboratory, with the Percepta test now available to a limited number of institutions around the country.

16 Apr 2015

Ancient natural compound can protect the heart from hypertrophy

A natural compound derived from the bark of the magnolia tree, can protect the heart from hypertrophy, a thickening of cardiac muscle often caused by chronic high blood pressure that can lead to heart failure, researchers report in the April 14 issue of the online journal Nature Communications.

15 Apr 2015

Veracyte, GE parnter to develop new solutions to improve disease diagnosis

Veracyte, Inc., a molecular diagnostic company pioneering the field of molecular cytology, and GE today announced a research collaboration to develop new solutions that can improve disease diagnosis.

14 Apr 2015

New study describes way to regenerate lung tissue after injury

A new collaborative study describes a way that lung tissue can regenerate after injury. The team found that lung tissue has more dexterity in repairing tissue than once thought.

13 Apr 2015

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation...

13 Apr 2015

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.

13 Apr 2015

Study explores the impact of costly hepatitis C drugs on Rhode Island's prison system

A new study finds that effective new hepatitis C drugs are so expensive the state of Rhode Island would have to spend almost twice its entire prison health budget to treat all its chronically infected inmates.

10 Apr 2015

Humans carry recessive disease mutations that can cause severe genetic disorders or prenatal death

Humans carry an average of one to two mutations per person that can cause severe genetic disorders or prenatal death when two copies of the same mutation are inherited, according to estimates published today in the journal GENETICS.

9 Apr 2015

Study may point to immediate cause of CF exacerbations

In the genetic disorder cystic fibrosis (CF), the most severe symptoms are recurring episodes of lung inflammation and bacterial infection (known as "exacerbations") that happen from one to three times a year and cause ever-increasing amounts of lung damage through the course of a CF patient's life.

9 Apr 2015

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen today announced that the European Commission approved a new use of Vectibix (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC).

6 Apr 2015

NASH patients more likely to have increased intestinal permeability, shows study

Non-alcoholic steatohepatitis (NASH), the more severe form of non-alcoholic fatty liver disease (NAFLD) that can progress to liver fibrosis and cirrhosis, is associated with leakiness of the intestinal wall, which in turn may worsen liver disease, according to research published in Cellular and Molecular Gastroenterology and Hepatology, the new basic science journal of the American Gastroenterological Association.

3 Apr 2015

Research breakthrough could help develop tools to repair damaged nerve cells

A team of researchers at the IRCM led by Frédéric Charron, PhD, in collaboration with bioengineers at McGill University, uncovered a new kind of synergy in the development of the nervous system, which explains an important mechanism required for neural circuits to form properly.

1 Apr 2015

Johns Hopkins researchers find link between premature aging of telomere and lung diseases

Lung diseases like emphysema and pulmonary fibrosis are common among people with malfunctioning telomeres, the “caps” or ends of chromosomes. Now, researchers from Johns Hopkins say they have discovered what goes wrong and why.

1 Apr 2015

Johns Hopkins researchers find link between premature aging of telomere and lung diseases

1 Apr 2015

New study opens door to preventative treatments for congenital diaphragmatic hernia

Congenital diaphragmatic hernia (CDH) is not as well known as muscular dystrophy and cystic fibrosis, but like them it is a life-threatening birth defect, and is just as common. Occurring in one in 3,000 births, CDH causes the guts and liver to protrude through a defective diaphragm and into the chest cavity, where they interfere with the lungs.

30 Mar 2015

UCSF professor wins Vilcek Prize in Biomedical Science

Peter Walter was chosen as winner of the Vilcek Prize in Biomedical Science for his pioneering work on how proteins are transported between cellular compartments and for unraveling the components of a regulatory mechanism that cells use to handle stress tied to the aggregation of misshapen proteins.

29 Mar 2015

GFT505 demonstrates dose-dependent efficacy on primary endpoint in phase 2 NASH trial

GENFIT, today announces topline results of the phase 2 GOLDEN-505 trial in NASH. Due to the unexpected rate of resolution of NASH in patients randomized to placebo who had early NASH (NAS of 3, placebo response rate>57%), along with the high number of sites for a limited sample size, the study as initially designed did not enable the trial to meet directly the primary endpoint.

27 Mar 2015

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that the European Commission has granted orphan medicinal product designation for RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 ("miR-21") for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

25 Mar 2015

Key finding may point to immediate cause of CF exacerbations

24 Mar 2015

Publicly insured Americans who undergo lung transplantation fare worse than their UK counterparts

Publicly insured Americans who undergo lung transplantation for cystic fibrosis fare markedly worse in the long run than both publicly insured patients in the United Kingdom and privately insured Americans, according to the results of a study conducted by researchers from Johns Hopkins in Baltimore and U.K. colleagues working in that nation's government-funded National Health Service.

24 Mar 2015

Fibrosis News and Research

Further Reading

Veracyte launches new genomic test to improve lung cancer diagnosis

Ancient natural compound can protect the heart from hypertrophy

Veracyte, GE parnter to develop new solutions to improve disease diagnosis

New study describes way to regenerate lung tissue after injury

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Study explores the impact of costly hepatitis C drugs on Rhode Island's prison system

Humans carry recessive disease mutations that can cause severe genetic disorders or prenatal death

Study may point to immediate cause of CF exacerbations

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

NASH patients more likely to have increased intestinal permeability, shows study

Research breakthrough could help develop tools to repair damaged nerve cells

Johns Hopkins researchers find link between premature aging of telomere and lung diseases

Johns Hopkins researchers find link between premature aging of telomere and lung diseases

New study opens door to preventative treatments for congenital diaphragmatic hernia

UCSF professor wins Vilcek Prize in Biomedical Science

GFT505 demonstrates dose-dependent efficacy on primary endpoint in phase 2 NASH trial

Regulus' RG-012 receives orphan medicinal product designation in EU for treatment of Alport syndrome

Key finding may point to immediate cause of CF exacerbations

Publicly insured Americans who undergo lung transplantation fare worse than their UK counterparts

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News